Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Ashmore, Smith & Nephew, AstraZeneca

(Sharecast News) - JPMorgan Cazenove nudged down its price target on Ashmore from 185.0p to 184.0p on Monday and reiterated its 'underweight' rating as it argued that the re-rating has gone too far. The bank noted that Ashmore's shares had rebounded by around 8% in the past month, driven by better market performance and a slower pace of net outflows in Q4 23.

It said that even though fiscal H1 24 results beat what seemed to it like a "stale" consensus, the H1 24 adjusted EBITDA was 10% below its expectations. As a result, the bank cut its adjusted earnings per share estimates by around 9% on average for FY24-27E.

JPM said that even though it forecasts a gradual net flow recovery, it does not expect a return to double-digit $bn net inflows.

"At 18.9x 2025E price-to-earnings (or 12.7x excluding excess capital) Ashmore is the most expensive stock within our traditional asset managers coverage," it said. "We believe the circa 25% multiple rerating since October 2023 has gone too far, and reiterate our underweight recommendation."

RBC Capital Markets reiterated its 'outperform' rating and 1,500.0p target price on Smith & Nephew ahead of the medical devices giant's fourth-quarter results later this month, saying it sees upside risk to current estimates.

Strong results from sector peers like Johnson & Johnson, Stryker and Zimmer Biomet suggest that the global hip and knee market expanded by a combined 7.1% in the fourth quarter, as surgery levels increased on the back of a "a return to normal phasing and secular growth in demand", RBC said.

"If Smith & Nephew's Ortho revenues have grown in line with the market, this implies up to 1% upside to Q4 group sales vs RBCe/consensus, or more if it takes share," the broker said ahead of the group's scheduled results on 27 February.

Smith & Nephew's shares have underperformed the wider sector by 10% so far in 2024, which could reflect "nervousness" around hitting margin guidance, RBC said. So the reaction to a strong fourth-quarter result could be strong.

"We also remain bullish on SN in the longer term, and continue to believe its valuation vs peers does not account for its competitive positioning or growth outlook."

Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Shares in AstraZeneca dropped on Thursday after fourth-quarter core earnings per share rose by just 7% year-on-year to $1.45, which was a 3% miss against consensus forecasts.

The stock, down nearly 2% on Monday, has now fallen 8.8% since the results were released and now stands at a 52-week low of 9,564.70p.

"The last time AZN moved that much on a print (3Q21), the magnitude of the EPS miss/subsequent downgrades was far greater," Barclays said.

As a result of the fourth-quarter numbers, Barclays trimmed its 2024 EPS forecasts by 2%. However, the bank still sees significant upside with a price target of 12,500.0p.

"We think this presents a compelling entry point for a best-in-class company," Barclays said.

Share this article

Related Sharecast Articles

London midday: Oil and mining stocks drag UK markets lower
(Sharecast News) - Losses in the mining and oil sectors were providing a drag on London's FTSE 100 on Monday, as investors scaled back their appetite for risk in light of rising geopolitical tensions in the Middle East.
US pre-open: Futures higher following last week's sell-off
(Sharecast News) - Wall Street futures were in the green ahead of the bell on Monday as market participants strapped in for the beginning of corporate earnings season.
London open: Israel-Iran tensions weigh on stocks early on
(Sharecast News) - Iran's attack on Israel overnight was weighing on London's stock market on Monday morning, with the FTSE 100 dropping 0.4% to 7,960 early on.
Asia report: Most markets fall on fresh geopolitical concerns
(Sharecast News) - Asia-Pacific markets were mixed but mostly lower on Monday, against a backdrop of escalating geopolitical tensions and ahead of key economic indicators.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.